Impact of Methionine Synthase Reductase Polymorphisms in Chronic Myeloid Leukemia Patients.

<b>Introduction：</b> Metabolism methionine and of folate play a vital function in cellular methylation reactions, DNA synthesis and epigenetic process.However, polymorphisms of methionine have received much attention in recent medical genetics research. <b>Objectives</b>: To ascertain whether the common polymorphisms of the <i>MTRR</i> (Methionine Synthase Reductase) A66G gene could play a role in affecting susceptibility to Chronic Myeloid Leukemia (CML) in Sudanese individuals. <b>Methods:</b> In a case-controlled study, we extracted and analyzed DNA from 200 CML patients and 100 healthy control subjects by the PCR-RFLP method. <b>Results:</b> We found no significant difference in age orgender between the patient group and controls. The <i>MTRR</i> A66G genotypes were distributed based on the Hardy-Weinberg equilibrium (<i>p</i> &amp;gt; 0.05). The variation of <i>MTRR</i> A66G was less significantly frequent in cases with CML (68.35%) than in controls (87%) (OR = 0.146, 95% CI = 0.162-0.662, <i>p</i> &amp;lt; 0.002). Additionally, AG and GG genotypes and G allele were reducing the CML risk (Odds ratio [OR] = 0.365; 95% CI [0.179-0.746]; <i>p</i> = 0.006; OR = 0.292; 95% CI [0.145-0.590]; <i>p</i> = 0.001 and OR = 0.146; 95% CI [0.162-0.662]; <i>p</i> = 0.002 and OR = 2.0; 95% CI [1.3853-2.817]; respectively, (<i>p</i> = 0.000)). <b>Conclusions:</b> Our data demonstrated that heterozygous and homozygous mutant genotypes of <i>MTRR</i> polymorphisms were associated with decreased risk of developing CML in the Sudanese population.